佳學(xué)基因遺傳病基因檢測機構(gòu)排名,三甲醫(yī)院的選擇

基因檢測就找佳學(xué)基因!

熱門搜索
  • 癲癇
  • 精神分裂癥
  • 魚鱗病
  • 白癜風
  • 唇腭裂
  • 多指并指
  • 特發(fā)性震顫
  • 白化病
  • 色素失禁癥
  • 狐臭
  • 斜視
  • 視網(wǎng)膜色素變性
  • 脊髓小腦萎縮
  • 軟骨發(fā)育不全
  • 血友病

客服電話

4001601189

在線咨詢

CONSULTATION

一鍵分享

CLICK SHARING

返回頂部

BACK TO TOP

分享基因科技,實現(xiàn)人人健康!
×
查病因,阻遺傳,哪里干?佳學(xué)基因準確有效服務(wù)好! 靶向用藥怎么搞,佳學(xué)基因測基因,優(yōu)化療效 風險基因哪里測,佳學(xué)基因
當前位置:????致電4001601189! > 檢測產(chǎn)品 > 疾病風險 > 腫瘤基因檢測 >

【佳學(xué)基因檢測】質(zhì)譜成像評估原發(fā)性口腔癌及其淋巴結(jié)轉(zhuǎn)移的分子瘤內(nèi)異質(zhì)性的預(yù)后價值

比較做了備注《Molecules》在.?2022 Aug 25;27(17):5458.發(fā)表了一篇題目為《質(zhì)譜成像評估原發(fā)性口腔癌及其淋巴結(jié)轉(zhuǎn)移的分子瘤內(nèi)異質(zhì)性的預(yù)后價值》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Agata Kurczyk,?Marta Gawin,?Piotr Paul,?Ewa Chmielik,?Tomasz Rutkowski,?Monika Pietrowska,?Piotr Wid?ak?等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展,進一步強調(diào)了基因信息檢測與分析的重要性。

佳學(xué)基因檢測】質(zhì)譜成像評估原發(fā)性口腔癌及其淋巴結(jié)轉(zhuǎn)移的分子瘤內(nèi)異質(zhì)性的預(yù)后價值

品牌基因檢測價格表還有嗎


比較做了備注《Molecules》在.?2022 Aug 25;27(17):5458.發(fā)表了一篇題目為《質(zhì)譜成像評估原發(fā)性口腔癌及其淋巴結(jié)轉(zhuǎn)移的分子瘤內(nèi)異質(zhì)性的預(yù)后價值》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Agata Kurczyk,?Marta Gawin,?Piotr Paul,?Ewa Chmielik,?Tomasz Rutkowski,?Monika Pietrowska,?Piotr Wid?ak?等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展,進一步強調(diào)了基因信息檢測與分析的重要性。


腫瘤靶向藥物及正確治療臨床研究內(nèi)容關(guān)鍵詞:


癌癥預(yù)后,頭頸部鱗狀細胞癌,瘤內(nèi)異質(zhì)性,長期結(jié)果,質(zhì)譜成像,腫瘤微環(huán)境


腫瘤靶向治療基因檢測臨床應(yīng)用結(jié)果


腫瘤內(nèi)異質(zhì)性 (ITH) 的不同方面與癌癥的發(fā)展及其對治療的反應(yīng)相關(guān),具有推測的預(yù)后價值。在這里,我們尋找通過質(zhì)譜成像 (MSI) 分析的表型 ITH 與頭頸癌預(yù)后之間的潛在關(guān)聯(lián)。該研究涉及從 77 名局部晚期口腔鱗狀細胞癌患者中切除的組織標本,其中 37 名患者的原發(fā)腫瘤和同步淋巴結(jié)轉(zhuǎn)移的匹配樣本進行了分析。對所有患者進行了 3 年的隨訪,將他們分為兩組:無疾病證據(jù)(NED,n = 41)和疾病進展(PD,n = 36)。在組織內(nèi)胰蛋白酶消化后,所有癌癥區(qū)域的肽圖都使用無監(jiān)督的方法進行分割,以揭示其內(nèi)在的異質(zhì)性。我們發(fā)現(xiàn) PD 組的腫瘤內(nèi)光譜相似性更高,NED 組在圖像分割過程中識別的簇的多樣性更高,這表明患者的 ITH 水平更高,結(jié)果更有利。與長期結(jié)果相關(guān)的分子成分的特征可能與參與免疫功能的蛋白質(zhì)有關(guān)。此外,觀察到 ITH 與組織病理學(xué)淋巴細胞宿主反應(yīng)之間存在正相關(guān)。因此,我們提出在預(yù)后較好的癌癥中,MSI 顯示的 ITH 水平較高可能反映了腫瘤微環(huán)境中異型成分的存在,例如浸潤免疫細胞增強了對治療的反應(yīng)。頭頸部鱗狀細胞癌;瘤內(nèi)異質(zhì)性;長期結(jié)果;質(zhì)譜成像;腫瘤微環(huán)境。


腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國際數(shù)據(jù)庫描述:


Different aspects of intra-tumor heterogeneity (ITH), which are associated with the development of cancer and its response to treatment, have postulated prognostic value. Here we searched for potential association between phenotypic ITH analyzed by mass spectrometry imaging (MSI) and prognosis of head and neck cancer. The study involved tissue specimens resected from 77 patients with locally advanced oral squamous cell carcinoma, including 37 patients where matched samples of primary tumor and synchronous lymph node metastases were analyzed. A 3-year follow-up was available for all patients which enabled their separation into two groups: with no evidence of disease (NED,?n?= 41) and with progressive disease (PD,?n?= 36). After on-tissue trypsin digestion, peptide maps of all cancer regions were segmented using an unsupervised approach to reveal their intrinsic heterogeneity. We found that intra-tumor similarity of spectra was higher in the PD group and diversity of clusters identified during image segmentation was higher in the NED group, which indicated a higher level of ITH in patients with more favorable outcomes. Signature of molecular components that correlated with long-term outcomes could be associated with proteins involved in the immune functions. Furthermore, a positive correlation between ITH and histopathological lymphocytic host response was observed. Hence, we proposed that a higher level of ITH revealed by MSI in cancers with a better prognosis could reflect the presence of heterotypic components of tumor microenvironment such as infiltrating immune cells enhancing the response to the treatment.Keywords:?cancer prognosis; head and neck squamous cell carcinoma; intratumor heterogeneity; long-term outcome; mass spectrometry imaging; tumor microenvironment.



(責任編輯:佳學(xué)基因)
頂一下
(0)
0%
踩一下
(0)
0%
推薦內(nèi)容:
來了,就說兩句!
請自覺遵守互聯(lián)網(wǎng)相關(guān)的政策法規(guī),嚴禁發(fā)布色情、暴力、反動的言論。
評價:
表情:
用戶名: 驗證碼: 點擊我更換圖片

Copyright © 2013-2033 網(wǎng)站由佳學(xué)基因醫(yī)學(xué)技術(shù)(北京)有限公司,湖北佳學(xué)基因醫(yī)學(xué)檢驗實驗室有限公司所有 京ICP備16057506號-1;鄂ICP備2021017120號-1

設(shè)計制作 基因解碼基因檢測信息技術(shù)部